Ask AI
ProCE Banner Activity

A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

Podcast

Listen to expert perspectives on selecting optimal therapy for patients with CLL, with a focus on how BTK inhibitor resistance mutations are assessed and how they affect therapy choice. 

Released: October 01, 2024

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca

AstraZeneca

Financial Disclosures

Primary Author

Matthew S. Davids, MD, MMSc

Chief, Division of Lymphoma
Harold and Virginia Lash Endowed Chair in Lymphoma Research 
Dana-Farber Cancer Institute
Leader, Lymphoma Program, Harvard Cancer Consortium
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Matthew S. Davids, MD, MMSc: consultant: AbbVie, Ascentage, AstraZeneca, BeiGene/BeOne, Bristol Myers Squibb, Galapagos, Genentech, Genmab, Janssen, Lilly, MEI Pharma, Merck, Nuvalent, Schrödinger; researcher: Ascentage, AstraZeneca, MEI Pharma.

Lindsey Roeker, MD

Assistant Attending
CLL Program Director
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Lindsey Roeker, MD: consultant/advisor/speaker: AbbVie, Ascentage, AstraZeneca, BeiGene, Curio, DAVA, Janssen, Loxo Oncology, Pharmacyclics, Pfizer; data and safety monitoring committee: Ascentage; owner (minority ownership interest): Abbott; researcher (paid to institution): AbbVie, Adaptive Biotechnologies, Aptose Biosciences, AstraZeneca, Dren Bio, Genentech, Loxo Oncology, Pfizer, Qilu Puget Sound Biotherapeutics.